NEW YORK, Dec. 11 - Genaissance Pharmaceuticals has given AstraZeneca access to specific HAP markers and its DecoGen informatics platform to help the pharmaceutical firm bolster its drug-discovery efforts, Genaissance said on Tuesday.
Financial or research details of the deal, the third of its kind that Genaissance has struck with a major pharmaceutical company, were not disclosed.
Genaissance, of New Haven, Conn., has a cache of almost 100,000 haplotypes from more than 5,400 genes and said it intends to discover haplotypes for all human genes.
"Pharmacogenomics has an expanding role to play in drug discovery and development," John Stageman, AstraZeneca's vice president of enabling science and technology, said in a statement. "AstraZeneca looks forward to using Genaissance's advanced HAP Technology platform and evaluating its potential to accelerate our internal efforts."